Nemvaleukin alfa, a modified interleukin-2 cytokine, as monotherapy and with pembrolizumab in patients with advanced solid tumors (ARTISTRY-1)

calendar icon

Source: Journal for ImmunoTherapy in Cancer (JITC)
Phase: Phase 1/2
Candidate Study: ARTISTRY-1
Indication: Advanced Solid Tumors

>> View Publication

All Publications